Led · Series C · Oct 2025

Electra Therapeutics is advancing a new class of precision therapies designed to eliminate overactive immune cells while sparing normal immune function, aiming to treat life-threatening immune-mediated and oncologic conditions. Its lead candidate, ELA026, is an antibody that targets Signal Regulatory Proteins (SIRP) and is being positioned as the first FDA-approved therapy for secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory disease with no approved treatments. Early Phase 1b data showed 100 percent survival at eight weeks in frontline-treated sHLH patients, earning the program FDA Breakthrough Therapy and EMA Priority Medicines designations. The company plans to use newly raised capital to run a global registrational Phase 2/3 study of ELA026 in sHLH and to expand the molecule into hematologic cancers. Proceeds will also fund clinical proof-of-mechanism for a second SIRP-targeting program, ELA822, that has broad potential in immunology and inflammation. Electra’s team, led by President & CEO Kathy Dong, PharmD, MBA, has a track record of translating novel biology into first-in-class therapies. The company’s current financial momentum is driven by a USD 183 million Series C round co-led by EQT Life Sciences and Nextech with participation from strategic and institutional investors.

Participated · Series C · Jan 2025

Be Bio pioneers Engineered B Cell Medicines (BCMs), a platform that programs primary human B cells to produce therapeutic proteins continuously and durably. Its lead programs, BE-101 (Factor IX for hemophilia B) and BE-102 (alkaline phosphatase for hypophosphatasia), are built on this BCM platform and designed to be titratable and re-dosable without preconditioning. BE-101 has an FDA-cleared IND (May 2024), Fast Track designation (September 2024), and is being evaluated in the Phase 1/2 BeCoMe-9 trial to generate clinical proof-of-concept. BE-102 has been selected as a development candidate and is being advanced toward the clinic. The company says proceeds from the Series C will advance BE-101 through proof-of-concept and move BE-102 into clinical development. Be Bio was founded in October 2020 and is based in Cambridge, Mass. Be Biopharma develops engineered B Cell Medicines (BCMs) to improve outcomes for patients with Hemophilia B, other genetic diseases, cancer, and other serious conditions. Its lead program, BE-101, is engineered to insert the human Factor IX (FIX) gene into primary human B cells to enable continuous expression of active FIX. BE-101 aims to deliver sustained therapeutic FIX activity with a single infusion, with the flexibility to be titrated or re-dosed and without the need for preconditioning. The US FDA cleared the BE-101 IND in May 2024 and granted Fast Track designation in September 2024. The company has initiated the Phase 1/2 BeCoMe-9 trial and plans to use the new funding to achieve clinical proof of concept for BE-101 and to advance BE-102. Be Biopharma is led by CEO Joanne Smith-Farrell and is based in Cambridge, MA. Be Biopharma develops Engineered B Cell Medicines (BeCM), operating autologous and allogeneic B‑cell therapy platforms. The company is advancing a broad pipeline initially focused on rare disease and cancer. As it develops its platform, Be Biopharma plans to expand into infectious disease, neurological conditions and autoimmune disease. It closed a $130M financing to support platform advancement and to progress pipeline candidates toward the clinic, bringing total investment to over $180M. Founded in October 2020 and based in Cambridge, MA, the company was launched by Longwood Fund and B‑cell engineering pioneers David Rawlings and Richard James, and is led by CEO Joanne Smith‑Farrell. Be Biopharma develops engineered B cells as a new category of medicines, using the human body's native protein factories to produce therapeutic proteins. The company aims to precisely engineer B cells to exploit their high protein production, selective tissue targeting, and potentially long programmable lifetimes. Be Bio intends its medicines to be durable, re-dosable, and administered without toxic conditioning, opening avenues to treat cancer, autoimmune diseases, monogenic disorders, and enhance responses to infectious pathogens. The platform builds on pioneering work by David Rawlings and Richard James at Seattle Children’s Research Institute. Leadership and scientific founders include Longwood Fund, David Rawlings, Richard James, David Steinberg (CEO and co-founder), Aleks Radovic-Moreno, and Lea Hachigian. The company is based in Cambridge, Mass.

Participated · Series C · Mar 2024

Alumis is a clinical-stage biopharmaceutical company based in San Francisco that develops oral therapies using a precision approach to optimize outcomes for patients with immune-mediated diseases. Its lead candidate, ESK-001, is a highly selective allosteric TYK2 inhibitor being evaluated for moderate to severe plaque psoriasis, systemic lupus erythematosus (SLE), and non-infectious uveitis. Alumis is also developing A-005, a brain-penetrant allosteric TYK2 inhibitor aimed at neuroinflammatory and neurodegenerative diseases, which was anticipated to enter a Phase 1 trial in the first half of 2024. The company leverages precision data analytics and a multi-platform approach to advance a pipeline of oral therapies and to power target discovery and clinical development. Alumis raised an upsized $259M Series C to support further clinical development of ESK-001, exploration of additional autoimmune indications, advancement of A-005, and earlier-stage internal programs. CEO Martin Babler said the investment will support continued clinical development, building on promising data demonstrating sustained target inhibition and a potentially best-in-class oral TYK2 inhibitor profile. Alumis (formerly Esker Therapeutics) combines a precision analytics platform with immunology drug discovery to develop targeted therapies for autoimmune disease. Its lead program, ESK-001, is a highly selective TYK2 inhibitor being developed for psoriasis with greater selectivity for TYK2 over JAK1 compared to current therapies in development. The company says it is advancing ESK-001 into the clinic while initiating multiple pipeline programs informed by its analytics platform. Alumis was incubated by Foresite Labs and is backed by Foresite Capital; the team has expanded across research, development and business development. The organization recently changed its name to reflect its precision-immunology focus and plans to build additional assets from internal and external sources. Proceeds from the recent financing will be used to continue advancing the pipeline and potentially add assets to the portfolio. Esker Therapeutics is building precision therapies that target the patient populations most likely to benefit from them, with an emphasis on avoiding broad "all comer" approaches. Its lead program, ESK-001, is a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1 and is being evaluated in a Phase 1 trial in healthy volunteers for psoriasis. The company says ESK-001 demonstrated potent and highly selective TYK2 inhibition in preclinical studies, enabling higher dosing while avoiding JAK-associated side effects. Beyond ESK-001, Esker has additional discovery-stage assets focused on causal drivers across multiple autoimmune indications. Esker leverages a precision analytics platform powered by Foresite Labs that combines curated genetic, clinical and health-records data, a systems immunology toolkit, and patient-registry tools to inform target, pathway, indication, and patient-subset selection.

Participated · Series A · Jan 2024

Synnovation Therapeutics is a precision medicine company developing small-molecule therapies optimized to achieve best-in-class pharmacology against highly validated oncologic targets. The company’s lead program, SNV1521, is a potent, highly selective, CNS-penetrant PARP1 inhibitor now in a Phase I study and anticipating first patient dosing in the coming weeks. Its second program, SNV4818, is a mutant-selective PI3K-alpha inhibitor differentiated by strong selectivity for H1047X and moderate selectivity over E545/542X mutants. Synnovation was founded by a medicinal chemistry team with drug discovery experience that contributed to five approved drugs while at Incyte. The company launched in Wilmington, Del., with a $102 million Series A to advance its clinical and preclinical pipeline, including SNV1521 and SNV4818. Proceeds will fund advancement of the pipeline and additional programs aimed at delivering potentially best-in-class therapies that address liabilities in current standards of care.

Participated · Equity · Jun 2023

ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech based in Garching, Germany focused on advancing radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. Its lead candidate is n.c.a. 177Lu-edotreotide (ITM-11 / 177Lu-edotreotide), and the company supports a broad precision oncology pipeline including multiple Phase 3 studies. The company is led by CEO Dr. Andrew Cavey. ITM plans to use new capital to prepare for commercial readiness and potential market launch of its lead candidate. The company announced a non-dilutive debt financing agreement that will support late-stage development and commercial preparation. ITM is a radiopharmaceutical biotech company dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. Led by CEO Steffen Schuster and based in Munich, Germany, the company focuses on advancing radiopharmaceutical candidates. ITM intends to use the funds to advance and expand its radiopharmaceutical pipeline and to foster its development platform. The company will prepare commercial readiness for the potential market launch of its phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Proceeds will also enable expansion of manufacturing capabilities for production of alpha- and beta-emitting radioisotopes, including Lutetium-177(177Lu) and Actinium-225(225Ac). ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech focused on radiomolecular precision therapeutics and diagnostics (theranostics) and a broad Targeted Radionuclide Therapies (TRT) oncology pipeline. Its lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) is nearing the final stages of phase III development in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and ITM-31 (Lu-177 labeled 6A10 Fab-fragments) is in clinical studies for glioblastoma. The company is also a major radioisotope supplier and is expanding manufacturing and GMP capabilities for n.c.a. 177Lu and scaling GMP manufacturing for 225Ac to meet growing demand. Planned investments include a second state-of-the-art manufacturing facility in Germany, expanded in-house drug product manufacturing, and broader commercial infrastructure to accelerate global access. ITM has opened a U.S. headquarters in Princeton, New Jersey and established a subsidiary in Shanghai to support regional introduction of precision oncology products. The company says it will leverage nearly two decades of radiopharma expertise and its global network to improve patient access to targeted treatments. ITM develops targeted radiopharmaceutical diagnostics and therapeutics by combining medical radioisotopes with targeting molecules to treat hard-to-treat cancers. The company produces and supplies high-quality medical radioisotopes through a wide-reaching international supply network and leverages nearly two decades of radiopharma expertise. Its lead therapeutic candidate, ITM-11 (n.c.a. 177Lu-edotreotide), is being evaluated in two phase III trials (COMPETE and COMPOSE) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to use recent financing to finalize late-stage development of ITM-11, support potential commercialization and market launch efforts if approved, accelerate development of additional radiopharmaceutical candidates, and expand radioisotope supply capabilities. The company emphasizes precision oncology approaches that deliver radiation directly to tumors while minimizing exposure to healthy tissue. ITM is positioned as a global player in nuclear medicine, aiming to advance a broad proprietary pipeline and enable wider clinical adoption of targeted radionuclide therapies. ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company focused on development, production and global supply of targeted radionuclide diagnostics and therapeutics. The company produces high-quality medical radioisotopes and leverages nearly two decades of radiopharma expertise and an established global supply network. ITM has forward-integrated to build a broad pipeline, including lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) which is undergoing two phase III trials (COMPETE and COMPOSE), and companion diagnostic TOCscan® (68Ga-edotreotide). ITM-41 (n.c.a. 177Lu-zoledronate) is in preclinical development for osteosarcoma and bone metastases. The company is focused on expanding its presence in Asia and Greater China to meet growing patient needs. A recent strategic equity investment is intended to support late-stage development and broader commercialization efforts in the region.